Louis Damian, MD
Nephrology · Port Charlotte, FLNPI 1033612718
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 50.6% of the total. Reporting peaked in 2022 at $729 and has fallen 97.3% since, to $20 in 2025. That places this record below the midpoint for nephrology clinicians in FL, where the typical reported total is $1,407.
Across 53 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$617
- Veloxis Pharmaceuticals, Inc.$175
- Outset Medical Inc$109
- Aurinia Pharma U.S., Inc.$99
- Vifor Pharma, Inc.$80
- Nxstage Medical, Inc.$62
- plus $79 from 3 others
What the payments were for
- Food & beverage$1,221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 31 | $617 |
| Veloxis Pharmaceuticals, Inc. | 8 | $175 |
| Outset Medical Inc | 1 | $109 |
| Aurinia Pharma U.S., Inc. | 1 | $99 |
| Vifor Pharma, Inc. | 4 | $80 |
| Nxstage Medical, Inc. | 4 | $62 |
| Bayer | 2 | $39 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
How this compares
$1,221 in reported general payments places this provider in the 45th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 33 | $291 |
| Lisinopril | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Port Charlotte
- Rohit PankhaniyaPort Charlotte$34K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.